VX-880

Phase 3

Vertex Pharmaceuticals Incorporated (VRTX)

Orphan DrugFast TrackBreakthrough TherapyLearn about designations

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Type 1 Diabetes

LLYLY2963016

Phase 3

SABSHigh Dose SAB-142

Phase 2

CELZCELZ-201 Administration

Phase 2

View Full Landscape

Drug Information

Target Indication

Type 1 Diabetes

Mechanism of Action

Stem Cell-Derived Islets

Clinical Trial

NCT04786262

Last updated: 12/3/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VRTX

Vertex Pharmaceuticals Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

VX-661 plus ivacaftor combinationPhase 3

Cystic Fibrosis

IVAPhase 3

Cystic Fibrosis

LumacaftorPhase 3

Cystic Fibrosis

ELX/TEZ/IVAPhase 3

Cystic Fibrosis

Tezacaftor/IvacaftorPhase 3

Cystic Fibrosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts